SERVICE
健 康 管 理
每週一次的 Mounjaro
雙效腸泌素GIP+GLP-1RA
雙效腸泌素GIP+GLP-1RA
猛健樂(Mounjaro,學名:Tirzepatide)是一種新型雙重腸泌素藥物,同時作用於GLP-1(胰高血糖素樣肽-1)和GIP(葡萄糖依賴性胰島素增強多肽)受體。
適應症 Indications:
作為飲食及運動療法之外的輔助治療,用於改善第二型糖尿病成人病人之血糖控制。
說明: MOUNJARO 可做為單一療法或與其他糖尿病治療藥物合併使用。
As an adjunct to diet and exercise therapy, it is used to improve glycemic control in adult patients with type 2 diabetes.
Description: MOUNJARO can be used as monotherapy or in combination with other diabetes medications.
肥胖,是一種複雜的多因子疾病,不只會造成心血管疾病、糖尿病…等慢性疾病,也是現代人的罹癌風險因子之一。包括世界肥胖聯盟(WOF)、肥胖學會(TOS)、歐洲肥胖研究協會(EASO)…等醫療專業協會,都將肥胖視為需要「慢性病治療模式」的全球健康挑戰。因此減重、變瘦,不單單只是追求好看身型的表淺問題,避免肥胖而引起其他併發症,才是現代人的一大隱憂。
Obesity is a complex multifactorial disease that not only causes chronic diseases such as cardiovascular disease and diabetes, but is also one of the risk factors for cancer in modern people. Medical professional associations, including the World Obesity Federation (WOF), recognize obesity as a global health challenge that requires a “chronic disease treatment model.” Therefore, weight loss and thinning are not only a superficial problem of pursuing a good-looking body shape, but avoiding other complications caused by obesity is a major hidden worry for modern people.
注意事項與禁忌症 Precautions and contraindications
1.請勿將藥劑冷凍,經冷凍退冰後的猛健樂也不應使用。
2.懷孕或哺乳、預備懷孕的婦女勿使用。
3.如果藥物或過敏及預備懷孕者請事先徵詢醫師意見。
4.甲狀腺、肝、腎、胰臟有疾病症狀之患者需遵照醫囑謹慎使用。
5.禁用於個人或是家族有甲狀腺髓質癌 ( MTC ) 病史的病人或第二型多發性內分泌腫瘤綜合症 ( MEN 2 ) 的病人。
6.已知對 tirzepatide 或 MOUNJARO 的任何賦形劑嚴重過敏反應。
警語及注意事項:
應注意甲狀腺髓質癌、胰臟炎、併用促胰島素分泌劑或胰島素而發生的低血糖、過敏反應、急性腎損傷、嚴重胃腸疾病、有糖尿病視網膜病變史的病人之糖尿病視網膜病變併發症、急性膽囊疾病的風險。絕不要在病人間共用MOUNJARO KwikPen。
1. Do not freeze the medicine, and do not use Mengjianle after thawing.
2. Do not use if you are pregnant, breastfeeding or planning to become pregnant.
3. If you are taking medication or have allergies or are planning to get pregnant, please consult your doctor in advance.
4. Patients with symptoms of thyroid, liver, kidney, or pancreas disease should use the product with caution under doctor’s orders.
5. It is contraindicated for patients with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2).
6. Known severe allergic reaction to tirzepatide or any of the excipients of MOUNJARO.
Warnings and Precautions:
Attention should be paid to the risks of medullary thyroid cancer, pancreatitis, hypoglycemia caused by the use of insulin secretagogues or insulin, allergic reactions, acute kidney injury, severe gastrointestinal diseases, complications of diabetic retinopathy in patients with a history of diabetic retinopathy, and acute gallbladder disease. Never share the MOUNJARO KwikPen between patients.
1. Mounjaro may cause side effects such as nausea, constipation, vomiting, diarrhea, decreased appetite and hypoglycemia, but the symptoms usually subside after a few days or weeks and not everyone will experience them. ⚠️If you feel nauseous, we recommend that you take the following measures to relieve discomfort
Don’t eat when you are full
Drink plenty of water
Avoid eating and smelling foods that make you feel uncomfortable
Avoid high-fat or fried foods/spicy or strong-flavored foods
Avoid smoking or drinking
2. Shelf life after first use: 1 month
– Store below 30°C or in the refrigerator (2°C to 8°C)
– Put the injection pen cap back on and avoid light exposure
– Never share the injection pen or needle with others
3. Do not discard the KwikPen device or KwikPen cap after the first use! Each KwikPen contains 4 fixed doses, 1 dose per week
4. Discard the pen after completing the 4-week injection or 30 days after the first use, even if there is still medicine in the pen
注意事項與禁忌症 Precautions and contraindications
1.請勿將藥劑冷凍,經冷凍退冰後的猛健樂也不應使用。
2.懷孕或哺乳、預備懷孕的婦女勿使用。
3.如果藥物或過敏及預備懷孕者請事先徵詢醫師意見。
4.甲狀腺、肝、腎、胰臟有疾病症狀之患者需遵照醫囑謹慎使用。
5.禁用於個人或是家族有甲狀腺髓質癌 ( MTC ) 病史的病人或第二型多發性內分泌腫瘤綜合症 ( MEN 2 ) 的病人。
6.已知對 tirzepatide 或 MOUNJARO 的任何賦形劑嚴重過敏反應。
警語及注意事項:
應注意甲狀腺髓質癌、胰臟炎、併用促胰島素分泌劑或胰島素而發生的低血糖、過敏反應、急性腎損傷、嚴重胃腸疾病、有糖尿病視網膜病變史的病人之糖尿病視網膜病變併發症、急性膽囊疾病的風險。絕不要在病人間共用MOUNJARO KwikPen。
1. Do not freeze the medicine, and do not use Mengjianle after thawing.
2. Do not use if you are pregnant, breastfeeding or planning to become pregnant.
3. If you are taking medication or have allergies or are planning to get pregnant, please consult your doctor in advance.
4. Patients with symptoms of thyroid, liver, kidney, or pancreas disease should use the product with caution under doctor’s orders.
5. It is contraindicated for patients with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2).
6. Known severe allergic reaction to tirzepatide or any of the excipients of MOUNJARO.
Warnings and Precautions:
Attention should be paid to the risks of medullary thyroid cancer, pancreatitis, hypoglycemia caused by the use of insulin secretagogues or insulin, allergic reactions, acute kidney injury, severe gastrointestinal diseases, complications of diabetic retinopathy in patients with a history of diabetic retinopathy, and acute gallbladder disease. Never share the MOUNJARO KwikPen between patients.
1. Mounjaro may cause side effects such as nausea, constipation, vomiting, diarrhea, decreased appetite and hypoglycemia, but the symptoms usually subside after a few days or weeks and not everyone will experience them. ⚠️If you feel nauseous, we recommend that you take the following measures to relieve discomfort
Don’t eat when you are full
Drink plenty of water
Avoid eating and smelling foods that make you feel uncomfortable
Avoid high-fat or fried foods/spicy or strong-flavored foods
Avoid smoking or drinking
2. Shelf life after first use: 1 month
– Store below 30°C or in the refrigerator (2°C to 8°C)
– Put the injection pen cap back on and avoid light exposure
– Never share the injection pen or needle with others
3. Do not discard the KwikPen device or KwikPen cap after the first use! Each KwikPen contains 4 fixed doses, 1 dose per week
4. Discard the pen after completing the 4-week injection or 30 days after the first use, even if there is still medicine in the pen